ST. LOUIS, Feb. 21, 2023 (GLOBE NEWSWIRE) — stereotaxis STXSa pioneer and global leader in surgical robotics for minimally invasive endovascular procedures, today announced that David Fischel, Chairman and CEO, will be attending Cowen 43approx Annual health conference.
Mr. Fischel will discuss Stereotaxis’ business and technology during a fireside chat with Josh Jennings, Cowen’s Managing Director and Senior Research Analyst, on Monday, March 6, 2023 at 11:10 am ET. Mr. Fischel will be available for one-on-one meetings for the remainder of the day.
“We look forward to joining Cowen and sharing Stereotaxis’ differentiated technology, clinical value and growth strategy with investors,” said Mr. Fischel.
About stereotaxes
stereotaxis STXS is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments and information solutions for the interventional laboratory. These innovations help physicians deliver unmatched patient care with robotic precision and safety, expand access to minimally invasive therapy, and improve productivity, connectivity and intelligence in the operating room. Stereotaxis technology has been used to treat over 100,000 patients in the United States, Europe, Asia and elsewhere. For more information, please visit www.stereotaxis.com.
Investor contacts:
David L Fischel
Chairman and Chief Executive Officer
Kimberly Peery
CFO
314-678-6100
Investors@Stereotaxis.com
[ad_2]
Source story
